Introduction
Alcoholic liver disease (ALD) is a progressive hepatic disorder driven by chronic alcohol exposure, characterized by steatosis, inflammation, oxidative injury, hepatocyte apoptosis, and eventual fibrosis.1 Increasing scientific attention has focused on naturally derived bioactive compounds as adjunct or alternative therapeutic agents due to their multitargeted actions, relatively low toxicity, and ability to modulate key pathogenic pathways involved in ALD progression.
Natural compounds improving lipid metabolism
A major therapeutic target in ALD is dysregulated lipid metabolism leading to hepatic steatosis. Curcumin, the principal curcuminoid of turmeric, reduces lipid accumulation in hepatocytes via modulation of the Nrf2–FXR signaling axis and suppression of reactive oxygen species (ROS) generation. Dihydroquercetin, a flavonoid found in onions and milk thistle, activates the SIRT1–AMPK pathway, downregulating SREBP1 and reducing lipogenesis. Tanshinone IIA from Salvia miltiorrhiza inhibits fatty acid synthesis while enhancing fatty acid oxidation through regulation of the LXRα/SREBP1 pathway, thereby attenuating hepatic fat deposition.
Reduction of oxidative stress and redox imbalance
Oxidative stress plays a central role in ALD pathogenesis. Silymarin, extracted from Silybum marianum, enhances antioxidant defenses by increasing superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) while reducing malondialdehyde (MDA) levels. Isoorientin, present in buckwheat, exhibits strong antioxidant activity by elevating SOD and GSH-Px and reducing fibrosis-associated markers. Oleanolic acid, widely distributed in plant sources, restores redox balance through Nrf2-mediated antioxidant responses, thereby protecting against alcohol-induced hepatic injury.
Anti-inflammatory actions in ALD
Chronic inflammation is another hallmark of ALD. Anthocyanins suppress pro-inflammatory mediators such as TNF-α, IFN-γ, and TLR4, reducing hepatic inflammatory injury. Baicalin from Scutellaria baicalensis inhibits TLR4-mediated signaling pathways, protecting hepatocytes from immune-mediated damage. Puerarin and sophorol enhance alcohol metabolism via increased ADH and ALDH activity while simultaneously suppressing TNF-α, COX-2, and 5-LOX expression. Catechin, a polyphenol, inhibits NF-κB activation, thereby reducing inflammatory cascades and necrotic liver injury.
Regulation of programmed cell death
Apoptosis and autophagy imbalance contribute significantly to ALD progression. Corosolic acid activates AMPK signaling and restores ethanol-suppressed autophagy. Gastrodin inhibits caspase-3 activation, reducing hepatocyte apoptosis induced by ethanol toxicity. Ursolic acid similarly protects hepatic cells by suppressing CASP3-mediated apoptotic pathways, thereby mitigating alcohol-induced liver injury.
Modulation of gut microbiota and immune response
Emerging evidence highlights the gut–liver axis in ALD. Berberine improves intestinal microbial diversity by increasing Akkermansia muciniphila, restoring metabolic balance, and reducing hepatic inflammation. It also promotes the activation of immunoregulatory G-MDSC-like cells, contributing to hepatic protection.
Multi-targeted hepatoprotective compounds
Several compounds exhibit pleiotropic mechanisms. Naringenin and naringin reduce oxidative stress, lipid accumulation, and hepatocyte apoptosis while improving inflammatory profiles. Hesperidin regulates lipid metabolism genes and reduces steatosis with antioxidant benefits. Quercetin activates AMPK and PI3K–Keap1–Nrf2 pathways, promoting lipophagy and reducing oxidative injury. Dihydromyricetin improves mitochondrial function and decreases ROS by regulating AMPK/SIRT1/PGC-1α signaling. Glycycoumarin activates Nrf2 and autophagy pathways, enhancing hepatoprotection. Lycopene improves gut microbial diversity while suppressing CYP2E1-mediated oxidative stress. Limonoids such as limonin exert hepatoprotective effects through combined antioxidant and anti-inflammatory actions.
Conclusion
Natural compounds offer a multi-dimensional therapeutic approach to alcoholic liver disease by targeting lipid metabolism, oxidative stress, inflammation, apoptosis, and gut microbiota dysregulation. Their pleiotropic mechanisms make them promising candidates for integrative hepatoprotection. However, advancing their clinical applicability will require improved delivery systems and robust human studies to fully harness their therapeutic potential.2
References:
- Ha Y, Jeong I, Kim TH. Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives. Biomedicines. 2022;10(10):2530. Published 2022 Oct 10. doi:10.3390/biomedicines10102530 https://pmc.ncbi.nlm.nih.gov/articles/PMC9599689/
- Yan J, Nie Y, Luo M, Chen Z, He B. Natural Compounds: A Potential Treatment for Alcoholic Liver Disease?. Front Pharmacol. 2021;12:694475. Published 2021 Jul 5. doi:10.3389/fphar.2021.694475 https://pmc.ncbi.nlm.nih.gov/articles/PMC8287649/#s4